Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GZR18 in obese adults with moderate to severe obstructive sleep apnea not using positive airway pressure
CTR20261125Phase 3Active
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Apr 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity comparing GZR18 with Placebo (2 arms). Primary endpoint: Change from baseline in apnea-hypopnea index. Started Apr 2026; status: active.
02
Drugs
bofanglutide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on CTR20261125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261125.